Skip to main content

Table 2 Occurrence of cardiovascular events during 10-year follow-up, according to categories of coronary artery calcium score

From: Value of addition of coronary artery calcium to risk scores in the prediction of major cardiovascular events in patients with type 2 diabetes

CACS

(Agatston units)

Event

Ā Ā 

MACE

(nā€‰=ā€‰90)

MI

(nā€‰=ā€‰36)

Stroke

(nā€‰=ā€‰36)

CV death

(nā€‰=ā€‰34)

MI or

CV death

(nā€‰=ā€‰62)

0 (nā€‰=ā€‰174)

Proportion with event

5/174 (2.9%)

0

5/174 (2.9%)

0

0

Rate per 1,000 person-years

2.96

0

2.96

0

0

Ā 

Hazard ratio*

1 (ref.)

Ā Ā Ā Ā 

1ā€“100 (nā€‰=ā€‰229)

Proportion with event

19/229 (8.3%)

8/229 (3.5%)

6/229 (2.6%)

6/229 (2.6%)

13/229 (5.7%)

Rate per 1,000 person-years

8.83

3.66

2.76

2.72

5.95

Ā 

Unadjusted hazard ratio

3.00 (1.12ā€“8.04)

pā€‰=ā€‰0.029

Ā Ā Ā Ā 
Ā 

Adjusted hazard ratio

2.92 (1.06ā€“7.86)

pā€‰=ā€‰0.033

Ā Ā Ā Ā 

101ā€“300 (nā€‰=ā€‰131)

Proportion with event

23/131 (17.6%)

6/131 (4.6%)

12/131 (9.2%)

9/131 (6.9%)

14/131 (10.7%)

Rate per 1,000 person-years

19.74

4.94

10.07

7.23

11.53

Ā 

Unadjusted hazard ratio

6.78 (2.58ā€“17.83)

pā€‰<ā€‰0.001

Ā Ā Ā Ā 
Ā 

Adjusted hazard ratio

6.53 (2.47ā€“17.29)

pā€‰<ā€‰0.001

Ā Ā Ā Ā 

ā€‰>ā€‰300 (nā€‰=ā€‰201)

Proportion with event

43/201 (21.4%)

22/201 (10.9%)

13/201 (6.5%)

19/201 (9.5%)

35/201 (17.4%)

Rate per 1,000 person-years

24.94

12.45

7.25

10.30

19.81

Ā 

Unadjusted hazard ratio

8.68 (3.44ā€“21.90)

p ā€‰<ā€‰0.001

Ā Ā Ā Ā 
Ā 

Adjusted hazard ratio

8.30 (3.28ā€“21.00)

pā€‰<ā€‰0.001

Ā Ā Ā Ā 
  1. CACSā€‰=ā€‰coronary arteries calcium score (Agatston units); CVā€‰=ā€‰cardiovascular; MACEā€‰=ā€‰major adverse cardiovascular events; MIā€‰=ā€‰myocardial infarction
  2. *Hazard ratios are presented for MACE only due to wide confidence intervals secondary to low number of events in the individual endpoints. Adjustment was made for age, sex, duration of diabetes, insulin treatment, glycated hemoglobin, presence of retinopathy, nephropathy, neuropathy, creatinine clearance, prior CVA/TIA and medication treatment with aspirin or statin at enrolment, as well as PCE 10-year risk score (%) and MESA(without CACS) 10-year risk score (%)